ArticleMethodsX2026
Phase I trial combining sulfasalazine and gamma knife radiosurgery for recurrent glioblastoma.
Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent glioblastoma (GBM) remains a therapeutic challenge with poor prognosis and limited treatment options. This phase I, open-label, dose-escalation trial investigates the safety and tolerability of combining sulfasalazine, a cystine/glutamate antiporter-inhibitor, with gamma knife radiosurgery (GKRS) for patients with recurrent GBM. Sulfasalazine is hypothesized to potentiate radiotherapy by depleting tumor cells of glutathione (GSH), thereby enhancing susceptibility to reactive oxygen species generated during irradiation. The study aims to establish the maximum tolerated dose (MTD) of sulfasalazine in combination with GKRS and explore preliminary efficacy signals through imaging and clinical endpoints.•Primary objective: Determine the MTD of sulfasalazine combined with GKRS and recommend a dose for future•phase II trials using the common toxicity criteria for adverse events v4.0.•Secondary objectives: Assess changes in intratumoral GSH via GSH‑edited Magnetic Resonance Spectroscopy, tumor response by Response Assessment in Neuro‑Oncology criteria, metabolic response on Carbon-11 methionine positron emission tomography, quality of life, progression free and overall survival.•Design: Open-label, dose-escalation study enrolling 12-24 patients with recurrent GBM eligible for GKRS.Patients receive sulfasalazine for 3 days prior to GKRS, followed by 12 months of monitoring for adverse events, imaging biomarkers, radiological and survival outcomes. This trial will provide safety data and inform the potential of sulfasalazine as a radiosensitizer in GBM treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.